Trametinib Presents Potential New Standard-of-Care for Low-Grade Serous Ovarian Carcinoma
February 7th 2022Trametinib emerged as a novel therapeutic approach for low-grade serous carcinoma due to a high prevalence of activating mutations in the mitogen-activated protein kinase signaling pathway.
Read More
New Research Finds Patient Out-of-Pocket Spending Increased for Hepatitis B Medication
February 4th 2022During that time period, patients with high-deductible health plans spent on average $133 per 30-day supply, a cost threshold associated with a more than 50% rate of prescription abandonment, according to the researchers.
Read More